2015
Transcriptional Adaptation of Drug-tolerant Mycobacterium tuberculosis During Treatment of Human Tuberculosis
Walter ND, Dolganov GM, Garcia BJ, Worodria W, Andama A, Musisi E, Ayakaka I, Van TT, Voskuil MI, de Jong BC, Davidson RM, Fingerlin TE, Kechris K, Palmer C, Nahid P, Daley CL, Geraci M, Huang L, Cattamanchi A, Strong M, Schoolnik GK, Davis JL. Transcriptional Adaptation of Drug-tolerant Mycobacterium tuberculosis During Treatment of Human Tuberculosis. The Journal Of Infectious Diseases 2015, 212: 990-998. PMID: 25762787, PMCID: PMC4548467, DOI: 10.1093/infdis/jiv149.Peer-Reviewed Original ResearchConceptsDrug-tolerant bacilliDrug exposureDrug-susceptible pulmonary tuberculosisDrug-tolerant Mycobacterium tuberculosisDrug-susceptible Mycobacterium tuberculosisMycobacterium tuberculosisTuberculosis treatment regimensInitial drug exposureReverse transcription-polymerase chain reactionMessenger RNA expressionM. tuberculosis gene expressionDrug efflux pumpsSerial sputaPulmonary tuberculosisTreatment initiationNovel drug targetsTreatment regimensPolymerase chain reactionToxin-antitoxin genesHuman tuberculosisRate of declineDrug responsivenessStress signatureMarked downregulationDrug tolerance
2014
The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
Tsao C, Cutting E, Martin J, Oh W. The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer. Therapeutic Advances In Urology 2014, 6: 97-104. PMID: 24883107, PMCID: PMC4003844, DOI: 10.1177/1756287214528557.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerTreatment of metastatic castration-resistant prostate cancerCastration-resistant prostate cancerSurvival benefitProstate cancerDocetaxel-refractory metastatic castration-resistant prostate cancerRandomized phase III studyCause of drug resistancePhase III studySignificant survival benefitUS Food and Drug AdministrationTreatment of patientsDrug efflux pumpsFood and Drug AdministrationCytotoxic therapyIII studiesPreclinical modelsTherapeutic optionsClinical developmentCabazitaxelDrug resistanceP-glycoproteinPalliative endpointsFrequent causeEfflux pumps
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply